利比里亚埃博拉病毒病康复后妊娠、妊娠结局及婴儿生长发育:一项观察性队列研究
本研究为观察性队列研究,纳入PREVAIL III纵向研究中2014-2016年利比里亚埃博拉暴发期间暴露者,比较血清阳性康复者与血清阴性密切接触者的自报妊娠结局,并评估胎盘、母血、脐血、母乳和阴道分泌物中埃博拉RNA及婴儿生长发育。结果显示两组不良妊娠结局无显著差异(OR 1.13,95%CI 0.71-1.79),胎盘、脐血、母血及阴道拭子未检出埃博拉RNA,354份母乳样本中2份检出病毒RNA;血清阳性组婴儿中位体重和身长低于WHO标准,头围大于WHO标准,粗大运动里程碑与美国队列相似,但钳式抓握和早期发声轻度延迟。
要点
- 埃博拉康复者妊娠后,胎盘、脐血、母血及阴道拭子未检出埃博拉RNA。
- 两组不良妊娠结局无显著差异(OR 1.13,95%CI 0.71-1.79)。
- 血清阳性组婴儿中位体重和身长低于WHO标准,头围大于WHO标准。
核心结论
- 埃博拉病毒病康复者于急性期后约1年妊娠,围产期和产后埃博拉病毒再激活及不良出生结局的风险低。
- 作者认为,对妊娠的埃博拉康复者的照护不会给医护人员带来风险或使母亲及其后代遭受污名化。
- 作者认为,对计划妊娠者而言,埃博拉康复后安全妊娠完全可能。
研究设计与样本
- 观察性队列研究,纳入PREVAIL III纵向研究中2014-2016年利比里亚埃博拉暴发期间暴露者,分血清阳性康复组与血清阴性密切接触组。
- 2015年6月17日至2017年12月14日入组1566人,其中639人妊娠(血清阳性215人,血清阴性424人),589人报告妊娠结局(血清阳性206人,血清阴性383人)。
- 血清阳性组98名母亲的105名婴儿纳入出生队列,每6个月评估生长发育和神经发育至2年。
- 采用混合模型逻辑回归评估首次报告妊娠结局、年龄与研究组别的关联。
主要发现
- 两组不良妊娠结局的比值比无显著差异(OR 1.13,95%CI 0.71-1.79)。
- 54名血清阳性母亲分娩时采集的205份胎盘、脐血或母血样本及367份阴道拭子中未检出埃博拉RNA。
- 354份纵向母乳样本中2份检出病毒RNA。
- 54次分娩中57名婴儿除1名外抗埃博拉抗体均阳性,新生儿抗埃博拉IgG浓度高,6个月后下降。
- 与WHO标准相比,血清阳性组婴儿2年内中位体重和身长较低、中位头围较大;与美国队列相比粗大运动里程碑 attainment 相似,钳式抓握和早期发声轻度延迟。
关键数值与推荐
- 不良妊娠结局:血清阳性组 vs 血清阴性组 OR 1.13(95%CI 0.71-1.79),无显著差异。
- 埃博拉RNA检测:54名血清阳性母亲分娩时205份胎盘、脐血或母血样本及367份阴道拭子均未检出;354份母乳样本中2份检出。
- 婴儿抗体:54次分娩中57名婴儿除1名外抗埃博拉抗体均阳性。
- 婴儿生长:与WHO标准相比,血清阳性组婴儿中位体重和身长较低、中位头围较大。
- 神经发育:与美国队列相比粗大运动里程碑 attainment 相似,钳式抓握和早期发声轻度延迟。
临床怎么用
- 作者认为,对妊娠的埃博拉康复者的照护不会给医护人员带来风险或使母亲及其后代遭受污名化。
- 作者认为,对计划妊娠者而言,埃博拉康复后安全妊娠完全可能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Minimal data exist on pregnancy following recovery from Ebola in people of child-bearing potential (females aged roughly 18-45 years). The aim of this study was to assess viral persistence or reactivation in pregnancy, the frequency of placental transfer of anti-Ebola IgG antibodies, and pregnancy outcomes in this population. METHODS: In this observational cohort study, we studied self-reported pregnancies in two groups: seropositive people who had recovered from Ebola virus disease (seropositive group) and seronegative people who had close contact with people with Ebola (seronegative group). Participants had enrolled in the PREVAIL III longitudinal study and were exposed during the 2014-2016 Liberian Ebola outbreak. The primary outcome was pregnancy result. We assessed rates of livebirths and other pregnancy results in both study groups, and presence of Ebola RNA by PCR in samples of placenta, maternal and cord blood, breastmilk, and vaginal secretions from people who had recovered from Ebola who conceived a median of 14 months after acute Ebola virus disease. Mixed-model logistic regression evaluated associations between first-reported pregnancy outcome, age, and study group. Growth and neurodevelopment in the infants born to people in the seropositive group were assessed at 6-month intervals for 2 years. Data were accrued by PREVAIL III study staff. FINDINGS: 1566 participants were enrolled between June 17, 2015, and Dec 14, 2017, of whom 639 became pregnant (215 seropositive, 424 seronegative) and 589 reported pregnancy outcomes (206 seropositive, 383 seronegative). 105 infants born to 98 mothers in the seropositive group were enrolled in the birth cohort. Ebola RNA was not detected in 205 samples of placenta, cord blood, or maternal blood taken at birth from 54 mothers in the seropositive group, nor in 367 vaginal swabs. Viral RNA was found in two of 354 longitudinal breastmilk samples. All but one of 57 infants born during these 54 births were seropositive for anti-Ebola antibodies. Neonates showed high concentrations of anti-Ebola IgG, which declined after 6 months. Odds of adverse pregnancy outcome among the two groups were indistinguishable (OR 1·13, 95% CI 0·71-1·79). Compared with WHO standards, infants born to those in the seropositive group had lower median weight and length, and larger median head circumference over 2 years. Compared with a cohort from the USA accrual of gross motor developmental milestones was similar, whereas attainment of pincer grasp and early vocalisation were mildly delayed. INTERPRETATION: The risks of Ebola virus reactivation in the peripartum and postpartum period and of adverse birth outcomes are low in those who have recovered from Ebola virus disease and become pregnant approximately 1 year after acute Ebola virus disease. The implication for clinical practice is that care of people who are pregnant and who have recovered from Ebola can be offered without risks to health-care providers or stigmatisation of the mothers and their offspring. The implication for prospective mothers is that safe pregnancies are entirely possible after recovery from Ebola. FUNDING: National Institute of Allergy and Infectious Diseases and Liberia Ministry of Health.
引用
- Fallah MP, Reilly C, Van Ryn C, et al. Pregnancy, pregnancy outcomes, and infant growth and development after recovery from Ebola virus disease in Liberia: an observational cohort study. Lancet Glob Health. 2023. PMID: 37349033. doi:10.1016/S2214-109X(23)00210-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。